This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read ADMA Biologics’s 8K filing here.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
- Five stocks we like better than ADMA Biologics
- Buy P&G Now, Before It Sets A New All-Time High
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- 5 discounted opportunities for dividend growth investors
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 12/16 – 12/20
